TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02265341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study: NCT03119220

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit One
Description: Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
Study: NCT04134143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: A round patch of experimental skin tissue that the doctor applies over the ulcer
Study: NCT03227757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricuspid Valve Repair System
Description: Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
Study: NCT01801449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Study: NCT02162446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: satoreotide trizoxetan
Study: NCT02339779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fat transfer
Description: Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~1. First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~2. Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~3. Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast implant
Description: Implant-based reconstruction typically will occur as follows:~1. During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~2. The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~3. When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)
Study: NCT02703714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: 250 µg given subcutaneously (SC)
Study: NCT02633423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of PEEP before and after CPB
Description: PEEP will be set in order to reach an airway pressure of 5 cmH2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of PEEP before and after CPB
Description: PEEP will be set in order to reach an airway pressure of 5 cmH2O

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No use of PEEP before and after CPB(ZEEP)
Description: No PEEP will be used

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No use of PEEP before and after CPB(ZEEP)
Description: No PEEP will be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with CPAP during CPB
Description: A continuous Positive Airway Pressure (CPAP) will be applied during CPB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation with CPAP during CPB
Description: A continuous Positive Airway Pressure (CPAP) will be applied during CPB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No ventilation during CPB
Description: No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No ventilation during CPB
Description: No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
Study: NCT04058990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Paclitaxel-Coated PTCA Balloon Catheter
Description: Percutaneous Transluminal Coronary Angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
Description: Percutaneous Transluminal Coronary Angioplasty
Study: NCT03071185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve block, common peroneal nerve block
Description: For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral nerve block, common peroneal nerve block
Description: For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
Study: NCT01013012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramosetron with saline
Description: Group A : saline 1 ml, ramosetron 6μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron with dexamethasone
Description: Group B : dexamethasone 4 mg, ramosetron 6μg/kg
Study: NCT04057196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)
Description: The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
Study: NCT03570957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: MT-2990 solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: MT-2990 solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: MT-2990 solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-2990
Description: MT-2990 solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection in vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution for injection in vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection in vial
Study: NCT04358549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir to be administered as an oral tablet or made into a slurry for subjects who cannot swallow tablets

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care for individual study site as determined by each hospital's protocol
Study: NCT03573999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: 4.6 ml/kg will be administered before dura opening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl 7.5%
Description: 2 ml/kg will be administered before dura opening
Study: NCT03297346

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac imaging and circulating biomarkers
Description: Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
Study: NCT02800434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand allograft
Study: NCT03221569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: 0.3mg/kg IVPB over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 1ml intravenous push as placebo for double-blinding purposes
Study: NCT04632368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcendental Meditation
Description: TM, a mind-body intervention that can reduce sympathetic arousal and promote a state of relaxation and calm, will be offered to HCPs dealing with COVID-19 pandemic
Study: NCT03285685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
Study: NCT03988036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion; 200 mg; every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Biosimilar ABP 980
Description: Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
Study: NCT02086370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PBS
Description: the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical PBS
Description: the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
Study: NCT01091233

Intervention type: PROCEDURE
Intervention: paracentesis
Description: as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
Study: NCT00092014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate 35 mg
Description: Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Elemental Calcium
Description: Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risendronate placebo
Description: Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate placebo
Description: Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
Study: NCT03903081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily
Study: NCT01503320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral glutamine
Description: Dosage of glutamine: 0.57g/kg, \~ 30g/day= 3sachets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar appearing nutritional supplement without glutamine.
Study: NCT03903081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114 tablet
Description: administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo will be administered orally at a dose and frequency matched to HEC110114
Study: NCT01573598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given orally, once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 20 mg per day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone, 40 mg once per day, oral administration
Study: NCT01970358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly-ICLC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Study: NCT02265341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03030378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT02540447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Purge
Description: In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
Study: NCT00685490

Intervention type: PROCEDURE
Intervention: Vitrectomy w/o ILM peeling for macular edema with BRVO
Description: Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
Study: NCT03030378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Edodekin alfa
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo a MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02694549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaveoVasc
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
Study: NCT03030378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study: NCT05612282

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer

Intervention type: DIAGNOSTIC_TEST
Intervention: body composition analysis
Description: A body composition analysis was performed using the bioelectroimpedance method using the Maltron BioScan 920-2 analyzer
Study: NCT01364350

Intervention type: OTHER
Intervention: standard of care in general clinical practice
Description: Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
Study: NCT01095575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 3 ml, morphine 3mg
Description: On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 3 ml, morphine 3mg
Description: On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
Study: NCT05216848

Intervention type: OTHER
Intervention: Wijma Delivery Expectancy Questionnaire
Description: Simple questionaire identifying the level of fear of childbirth in pregnancy
Study: NCT02734056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Listening to music that the patient likes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control
Study: NCT04779333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP
Description: LEAP will be delivered through the typical 9 weekly BMT group sessions lasting 90 minutes. Plus wrist worn activity tracker \& facebook group.